Michael T Lotze

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9090643/publications.pdf

Version: 2024-02-01

206 papers	35,809 citations	7561 77 h-index	3482 182 g-index
209 all docs	209 docs citations	209 times ranked	47323 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
2	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	4.3	3,122
3	High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nature Reviews Immunology, 2005, 5, 331-342.	10.6	2,218
4	High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993. Journal of Clinical Oncology, 1999, 17, 2105-2105.	0.8	1,810
5	The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. Journal of Experimental Medicine, 2005, 201, 1135-1143.	4.2	1,634
6	Autophagy promotes ferroptosis by degradation of ferritin. Autophagy, 2016, 12, 1425-1428.	4.3	1,318
7	<scp>PAMP</scp>s and <scp>DAMP</scp>s: signal 0s that spur autophagy and immunity. Immunological Reviews, 2012, 249, 158-175.	2.8	899
8	Endogenous HMGB1 regulates autophagy. Journal of Cell Biology, 2010, 190, 881-892.	2.3	819
9	Principles and Current Strategies for Targeting Autophagy for Cancer Treatment. Clinical Cancer Research, 2011, 17, 654-666.	3.2	789
10	HMGB1 in health and disease. Molecular Aspects of Medicine, 2014, 40, 1-116.	2.7	763
11	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
12	The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity. Cell Reports, 2017, 20, 1692-1704.	2.9	608
13	Inflammation and necrosis promote tumour growth. Nature Reviews Immunology, 2004, 4, 641-648.	10.6	592
14	The grateful dead: damageâ€associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunological Reviews, 2007, 220, 60-81.	2.8	565
15	Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends in Immunology, 2007, 28, 429-436.	2.9	534
16	RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and Inflammation. Journal of Translational Medicine, 2009, 7, 17.	1.8	491
17	AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking System Xcâ€“ Activity. Current Biology, 2018, 28, 2388-2399.e5.	1.8	471
18	High-mobility group box 1 and cancer. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2010, 1799, 131-140.	0.9	442

#	Article	IF	Citations
19	High-Mobility Group Box 1, Oxidative Stress, and Disease. Antioxidants and Redox Signaling, 2011, 14, 1315-1335.	2.5	420
20	HMGB1 in Cancer: Good, Bad, or Both?. Clinical Cancer Research, 2013, 19, 4046-4057.	3.2	399
21	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	0.8	395
22	HSPA5 Regulates Ferroptotic Cell Death in Cancer Cells. Cancer Research, 2017, 77, 2064-2077.	0.4	353
23	PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis. Nature Communications, 2014, 5, 4436.	5.8	346
24	Masquerader: High Mobility Group Box-1 and Cancer. Clinical Cancer Research, 2007, 13, 2836-2848.	3.2	335
25	The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Molecular and Cellular Oncology, 2015, 2, e1054549.	0.3	301
26	Cancer and Inflammation: Promise for Biologic Therapy. Journal of Immunotherapy, 2010, 33, 335-351.	1.2	293
27	Clockophagy is a novel selective autophagy process favoring ferroptosis. Science Advances, 2019, 5, eaaw2238.	4.7	286
28	High-Mobility Group Box 1 Is Essential for Mitochondrial Quality Control. Cell Metabolism, 2011, 13, 701-711.	7.2	266
29	Clinical Trial to Assess the Safety, Feasibility, and Efficacy of Transferring a Potentially Anti-Arthritic Cytokine Gene to Human Joints with Rheumatoid Arthritis. University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Human Gene Therapy, 1996, 7, 1261-1280.	1.4	254
30	Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12611-12616.	3.3	234
31	p53/HMGB1 Complexes Regulate Autophagy and Apoptosis. Cancer Research, 2012, 72, 1996-2005.	0.4	220
32	Intracellular Hmgb1 Inhibits Inflammatory Nucleosome Release and Limits Acute Pancreatitis in Mice. Gastroenterology, 2014, 146, 1097-1107.e8.	0.6	200
33	Systemic inflammation and remote organ injury following trauma require HMGB1. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 293, R1538-R1544.	0.9	199
34	Progress in tuberculosis vaccine development and host-directed therapiesâ€"a state of the art review. Lancet Respiratory Medicine,the, 2014, 2, 301-320.	5.2	195
35	Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9. Journal of Hepatology, 2015, 63, 114-121.	1.8	189
36	Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 4402-4410.	0.7	187

#	Article	IF	Citations
37	PINK1 and PARK2 Suppress Pancreatic Tumorigenesis through Control of Mitochondrial Iron-Mediated Immunometabolism. Developmental Cell, 2018, 46, 441-455.e8.	3.1	176
38	Identification of baicalein as a ferroptosis inhibitor by natural product library screening. Biochemical and Biophysical Research Communications, 2016, 473, 775-780.	1.0	174
39	Cytosolic HMGB1 controls the cellular autophagy/apoptosis checkpoint during inflammation. Journal of Clinical Investigation, 2015, 125, 1098-1110.	3.9	173
40	Receptor-mediated signalling in plants: molecular patterns and programmes. Journal of Experimental Botany, 2009, 60, 3645-3654.	2.4	163
41	Signaling of High Mobility Group Box 1 (HMGB1) through Toll-like Receptor 4 in Macrophages Requires CD14. Molecular Medicine, 2013, 19, 88-98.	1.9	161
42	Eosinophilic Granulocytes and Damage-associated Molecular Pattern Molecules (DAMPs). Journal of Immunotherapy, 2007, 30, 16-28.	1.2	152
43	Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. Journal of Leukocyte Biology, 2009, 86, 633-643.	1.5	149
44	Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Annals of Oncology, 2019, 30, 1902-1913.	0.6	144
45	Addicted to Death. Journal of Immunotherapy, 2005, 28, 1-9.	1.2	140
46	The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 7031-7036.	3.3	139
47	HMGB1: The Central Cytokine for All Lymphoid Cells. Frontiers in Immunology, 2013, 4, 68.	2.2	137
48	Inhibition of Aurora Kinase A Induces Necroptosis inÂPancreaticÂCarcinoma. Gastroenterology, 2017, 153, 1429-1443.e5.	0.6	137
49	Inhibiting Systemic Autophagy during Interleukin 2 Immunotherapy Promotes Long-term Tumor Regression. Cancer Research, 2012, 72, 2791-2801.	0.4	133
50	Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps. BMC Cancer, 2018, 18, 678.	1.1	133
51	A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. Clinical Cancer Research, 2020, 26, 3126-3134.	3.2	133
52	Zinc in innate and adaptive tumor immunity. Journal of Translational Medicine, 2010, 8, 118.	1.8	129
53	Autophagy inhibition in combination cancer treatment. Current Opinion in Investigational Drugs, 2009, 10, 1269-79.	2.3	127
54	IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Neuro-Oncology, 2016, 18, 1402-1412.	0.6	126

#	Article	IF	Citations
55	Cell-Mediated Autophagy Promotes Cancer Cell Survival. Cancer Research, 2012, 72, 2970-2979.	0.4	122
56	Cell Death and DAMPs in Acute Pancreatitis. Molecular Medicine, 2014, 20, 466-477.	1.9	119
57	Consensus nomenclature for CD8⁺T cell phenotypes in cancer. OncoImmunology, 2015, 4, e998538.	2.1	119
58	High Mobility Group Box 1 (HMGB1) Activates an Autophagic Response to Oxidative Stress. Antioxidants and Redox Signaling, 2011, 15, 2185-2195.	2.5	118
59	DAMPs and autophagy. Autophagy, 2013, 9, 451-458.	4.3	118
60	HMGB1 as a potential biomarker and therapeutic target for severe COVID-19. Heliyon, 2020, 6, e05672.	1.4	118
61	DAMPs, ageing, and cancer: The â€˜DAMP Hypothesisâ€™. Ageing Research Reviews, 2015, 24, 3-16.	5.0	117
62	Cutting Edge: High-Mobility Group Box 1 Preconditioning Protects against Liver Ischemia-Reperfusion Injury. Journal of Immunology, 2006, 176, 7154-7158.	0.4	113
63	The Enhanced Tumor Selectivity of an Oncolytic Vaccinia Lacking the Host Range and Antiapoptosis Genes SPI-1 and SPI-2. Cancer Research, 2005, 65, 9991-9998.	0.4	111
64	High Mobility Group Box I (HMGB1) Release From Tumor Cells After Treatment: Implications for Development of Targeted Chemoimmunotherapy. Journal of Immunotherapy, 2007, 30, 596-606.	1.2	109
65	Increasing numbers of hepatic dendritic cells promote HMGB1-mediated ischemia-reperfusion injury. Journal of Leukocyte Biology, 2007, 81, 119-128.	1.5	107
66	Quercetin Prevents LPS-Induced High-Mobility Group Box 1 Release and Proinflammatory Function. American Journal of Respiratory Cell and Molecular Biology, 2009, 41, 651-660.	1.4	106
67	Paucity of dendritic cells in pancreatic cancer. Surgery, 2002, 131, 135-138.	1.0	105
68	JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice. Gastroenterology, 2018, 154, 1480-1493.	0.6	105
69	Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer. Cell Research, 2017, 27, 916-932.	5.7	103
70	Metabolic regulation by HMGB1-mediated autophagy and mitophagy. Autophagy, 2011, 7, 1256-1258.	4.3	102
71	Damage associated molecular pattern molecules. Clinical Immunology, 2007, 124, 1-4.	1.4	100
72	5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers. , 2016, 4, 65.		100

#	Article	IF	Citations
73	Natural killerâ€“dendritic cell cross-talk in cancer immunotherapy. Expert Opinion on Biological Therapy, 2005, 5, 1303-1315.	1.4	99
74	Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1. Molecular Immunology, 2005, 42, 433-444.	1.0	98
75	Tumor immunity times out: TIM-3 and HMGB1. Nature Immunology, 2012, 13, 808-810.	7.0	96
76	Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. , 1998, 78, 196-201.		95
77	A Janus Tale of Two Active High Mobility Group Box 1 (HMGB1) Redox States. Molecular Medicine, 2012, 18, 1360-1362.	1.9	91
78	High mobility group protein B1 controls liver cancer initiation through yesâ€associated protein â€dependent aerobic glycolysis. Hepatology, 2018, 67, 1823-1841.	3.6	88
79	AGER/RAGE-mediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathway. Autophagy, 2012, 8, 989-991.	4.3	82
80	Cytolytic cells induce HMGB1 release from melanoma cell lines. Journal of Leukocyte Biology, 2007, 81, 75-83.	1.5	81
81	High-Mobility Group Box 1 Promotes Hepatocellular Carcinoma Progression through miR-21â€“Mediated Matrix Metalloproteinase Activity. Cancer Research, 2015, 75, 1645-1656.	0.4	80
82	DNA released from neutrophil extracellular traps (NETs) activates pancreatic stellate cells and enhances pancreatic tumor growth. OncoImmunology, 2019, 8, e1605822.	2.1	77
83	The Receptor for Advanced Glycation End-Products (RAGE) Protects Pancreatic Tumor Cells Against Oxidative Injury. Antioxidants and Redox Signaling, 2011, 15, 2175-2184.	2.5	76
84	The NLRP3 inflammasome and bruton's tyrosine kinase in platelets co-regulate platelet activation, aggregation, and inÂvitro thrombus formation. Biochemical and Biophysical Research Communications, 2017, 483, 230-236.	1.0	74
85	RAGE regulates autophagy and apoptosis following oxidative injury. Autophagy, 2011, 7, 442-444.	4.3	71
86	Enhanced Neutrophil Extracellular Trap Formation in Acute Pancreatitis Contributes to Disease Severity and Is Reduced by Chloroquine. Frontiers in Immunology, 2019, 10, 28.	2.2	68
87	Tumor-Cell Death, Autophagy, and Immunity. New England Journal of Medicine, 2012, 366, 1156-1158.	13.9	66
88	Bortezomib Treatment Sensitizes Oncolytic HSV-1â€“Treated Tumors to NK Cell Immunotherapy. Clinical Cancer Research, 2016, 22, 5265-5276.	3.2	65
89	Recent Advances in Melanoma Staging and Therapy. Annals of Surgical Oncology, 1999, 6, 467-475.	0.7	64
90	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.		64

#	Article	IF	Citations
91	Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. , 2020, 8, e000878.		63
92	Dendritic Cell/Peptide Cancer Vaccines: Clinical Responsiveness and Epitope Spreading. Immunological Investigations, 2000, 29, 121-125.	1.0	61
93	High Mobility Group B1 Protein Suppresses the Human Plasmacytoid Dendritic Cell Response to TLR9 Agonists. Journal of Immunology, 2006, 177, 8701-8707.	0.4	59
94	Ethyl pyruvate administration inhibits hepatic tumor growth. Journal of Leukocyte Biology, 2009, 86, 599-607.	1.5	59
95	CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer. Gut, 2021, 70, 890-899.	6.1	59
96	Longitudinal Analysis of T and B Cell Receptor Repertoire Transcripts Reveal Dynamic Immune Response in COVID-19 Patients. Frontiers in Immunology, 2020, 11, 582010.	2.2	56
97	Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer. Annals of Surgical Oncology, 2020, 27, 898-906.	0.7	51
98	The Receptor for Advanced Glycation End Products Activates the AIM2 Inflammasome in Acute Pancreatitis. Journal of Immunology, 2016, 196, 4331-4337.	0.4	50
99	Life after death: targeting high mobility group box 1 in emergent cancer therapies. American Journal of Cancer Research, 2013, 3, 1-20.	1.4	50
100	The Receptor for Advanced Glycation End Products Promotes Pancreatic Carcinogenesis and Accumulation of Myeloid-Derived Suppressor Cells. Journal of Immunology, 2013, 190, 1372-1379.	0.4	47
101	Dealing with death: HMGB1 as a novel target for cancer therapy. Current Opinion in Investigational Drugs, 2003, 4, 1405-9.	2.3	47
102	Making cold malignant pleural effusions hot: driving novel immunotherapies. OncoImmunology, 2019, 8, e1554969.	2.1	46
103	Pivotal Advance: Inhibition of HMGB1 nuclear translocation as a mechanism for the anti-rheumatic effects of gold sodium thiomalate. Journal of Leukocyte Biology, 2008, 83, 31-38.	1.5	45
104	Platelet-derived high-mobility group box 1 promotes recruitment and suppresses apoptosis of monocytes. Biochemical and Biophysical Research Communications, 2016, 478, 143-148.	1.0	45
105	Johnny on the Spot-Chronic Inflammation Is Driven by HMGB1. Frontiers in Immunology, 2019, 10, 1561.	2.2	45
106	MÃ©nage Ã Trois in stress: DAMPs, redox and autophagy. Seminars in Cancer Biology, 2013, 23, 380-390.	4.3	43
107	Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy. Biomedicines, 2020, 8, 204.	1.4	41
108	PanIN-Specific Regulation of Wnt Signaling by HIF2Î± during Early Pancreatic Tumorigenesis. Cancer Research, 2013, 73, 4781-4790.	0.4	40

#	Article	IF	Citations
109	Retroviral Vectors for Use in Human Gene Therapy for Cancer, Gaucher Disease, and Arthritis. Annals of the New York Academy of Sciences, 1994, 716, 72-89.	1.8	39
110	DC/Lâ€SIGNs of hope in the COVIDâ€19 pandemic. Journal of Medical Virology, 2020, 92, 1396-1398.	2.5	39
111	Usage of T-cell receptor Vβ2 chain genes in fresh and cultured tumor-infiltrating lymphocytes from human melanoma. International Journal of Cancer, 1993, 54, 383-390.	2.3	38
112	High Mobility Group Box 1 (HMGB1) Phenotypic Role Revealed with Stress. Molecular Medicine, 2014, 20, 359-362.	1.9	37
113	Prolactin Promotes Fibrosis and Pancreatic Cancer Progression. Cancer Research, 2019, 79, 5316-5327.	0.4	36
114	Damage Associated Molecular Pattern Molecule-Induced microRNAs (DAMPmiRs) in Human Peripheral Blood Mononuclear Cells. PLoS ONE, 2012, 7, e38899.	1.1	35
115	Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational LoadÂTumor. Annals of Thoracic Surgery, 2017, 103, 1340-1349.	0.7	35
116	Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Medicine, 2021, 10, 5041-5050.	1.3	35
117	Murine Models of Cancer Cytokine Gene Therapy Using Interleukin-12. Annals of the New York Academy of Sciences, 1996, 795, 275-283.	1.8	34
118	Autophagy is required for IL-2-mediated fibroblast growth. Experimental Cell Research, 2013, 319, 556-565.	1.2	34
119	Interleukin-12 Gene Therapy Prevents Establishment of SCC VII Squamous Cell Carcinomas, Inhibits Tumor Growth, and Elicits Long-term Antitumor Immunity in Syngeneic C3H Mice. Laryngoscope, 1998, 108, 261-268.	1.1	32
120	Rapid flow cytometric measurement of cytokine-induced phosphorylation pathways [CIPP] in human peripheral blood leukocytes. Clinical Immunology, 2006, 121, 215-226.	1.4	32
121	A Tumor Cell-Selective Inhibitor of Mitogen-Activated Protein Kinase Phosphatases Sensitizes Breast Cancer Cells to Lymphokine-Activated Killer Cell Activity. Journal of Pharmacology and Experimental Therapeutics, 2017, 361, 39-50.	1.3	32
122	Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection. Journal of Translational Medicine, 2020, 18, 261.	1.8	32
123	Distant skin and soft tissue metastases from sarcomas. , 1998, 69, 94-98.		31
124	Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy. Cancer Gene Therapy, 2021, 28, 98-111.	2.2	30
125	Inhibiting Autophagy. Cancer Journal (Sudbury, Mass), 2013, 19, 341-347.	1.0	29
126	Extracellular DNA promotes colorectal tumor cell survival after cytotoxic chemotherapy. Journal of Surgical Research, 2018, 226, 181-191.	0.8	29

#	Article	IF	Citations
127	Blocking the interleukin 2 (IL2)-induced systemic autophagic syndrome promotes profound antitumor effects and limits toxicity. Autophagy, 2012, 8, 1264-1266.	4.3	28
128	Sweating the Small Stuff. Pancreas, 2013, 42, 740-759.	0.5	28
129	Serum and nutrient deprivation increase autophagic flux in intervertebral disc annulus fibrosus cells: an in vitro experimental study. European Spine Journal, 2019, 28, 993-1004.	1.0	28
130	Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma. American Journal of Roentgenology, 2020, 214, 362-369.	1.0	28
131	Perpetual change: autophagy, the endothelium, and response to vascular injury. Journal of Leukocyte Biology, 2017, 102, 221-235.	1.5	27
132	Pharmacologic Administration of Interleukinâ€2. Annals of the New York Academy of Sciences, 2009, 1182, 14-27.	1.8	26
133	Until Death Do Us Part: Necrosis and Oxidation Promote the Tumor Microenvironment. Transfusion Medicine and Hemotherapy, 2016, 43, 120-132.	0.7	26
134	TLR4-dependent upregulation of the platelet NLRP3 inflammasome promotes platelet aggregation in a murine model of hindlimb ischemia. Biochemical and Biophysical Research Communications, 2019, 508, 614-619.	1.0	25
135	Nuclear DAMP complex-mediated RAGE-dependent macrophage cellÂdeath. Biochemical and Biophysical Research Communications, 2015, 458, 650-655.	1.0	24
136	The platelet NLRP3 inflammasome is upregulated in a murine model of pancreatic cancer and promotes platelet aggregation and tumor growth. Annals of Hematology, 2019, 98, 1603-1610.	0.8	19
137	Actin-binding protein profilin1 promotes aggressiveness of clear-cell renal cell carcinoma cells. Journal of Biological Chemistry, 2020, 295, 15636-15649.	1.6	18
138	The Multifaceted Effects of Autophagy on the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1225, 99-114.	0.8	18
139	The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma. Medical Oncology, 2009, 26, 3-12.	1.2	17
140	The Adaptome as Biomarker for Assessing Cancer Immunity and Immunotherapy. Methods in Molecular Biology, 2020, 2055, 369-397.	0.4	17
141	Targeting Damage-Associated Molecular Pattern Molecules (DAMPs) and DAMP Receptors in Melanoma. Methods in Molecular Biology, 2014, 1102, 537-552.	0.4	17
142	Biological activities of cytokine-neutralizing hyaluronic acid-antibody conjugates. Wound Repair and Regeneration, 2010, 18, 302-310.	1.5	16
143	Clearance Kinetics and Matrix Binding Partners of the Receptor for Advanced Glycation End Products. PLoS ONE, 2014, 9, e88259.	1.1	16
144	Recombinant Human Interferon Alpha 2b Prevents and Reverses Experimental Pulmonary Hypertension. PLoS ONE, 2014, 9, e96720.	1.1	16

#	Article	IF	Citations
145	Dendritic Cells Pulsed With Apoptotic Squamous Cell Carcinoma Have Anti-Tumor Effects When Combined With Interleukin-2. Laryngoscope, 2001, 111, 1472-1478.	1.1	15
146	Identifying biomarkers and surrogates of tumors (cancer biometrics): correlation with immunotherapies and immune cells. Cancer Immunology, Immunotherapy, 2004, 53, 256-261.	2.0	15
147	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. , 2020, 8, e001583.		15
148	Not just nuclear proteins: 'novel' autophagy cancer treatment targets - p53 and HMGB1. Current Opinion in Investigational Drugs, 2008, 9, 1259-63.	2.3	14
149	Characterization and transduction of a retroviral vector encoding human interleukin-4 and herpes simplex virus-thymidine kinase for glioma tumor vaccine therapy. Cancer Gene Therapy, 2000, 7, 486-494.	2.2	13
150	Intrapleural interleukin-2â€“expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, e313-e328.	0.4	13
151	Novel chemokine-like activities of histones in tumor metastasis. Oncotarget, 2016, 7, 61728-61740.	0.8	13
152	Successful simultaneous measurement of cell membrane and cytokine induced phosphorylation pathways [CIPP] in human peripheral blood mononuclear cells. Journal of Immunological Methods, 2006, 313, 48-60.	0.6	12
153	Adoptive transfer of natural killer cells promotes the anti-tumor efficacy of T cells. Clinical Immunology, 2017, 177, 76-86.	1.4	12
154	Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation in Localized Pancreatic Cancer: A Caseâ€“Control Matched Analysis. Annals of Surgical Oncology, 2021, 28, 3779-3788.	0.7	12
155	SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma. Clinical and Translational Science, 2021, 14, 1822-1829.	1.5	12
156	Encouraging longâ€term survival following autophagy inhibition using neoadjuvant hydroxychloroquine and gemcitabine for highâ€risk patients with resectable pancreatic carcinoma. Cancer Medicine, 2021, 10, 7233-7241.	1.3	12
157	Different measures of HMGB1 location in cancer immunology. Methods in Enzymology, 2019, 629, 195-217.	0.4	11
158	Fighting Fire With Fire: Oncolytic Virotherapy for Thoracic Malignancies. Annals of Surgical Oncology, 2021, 28, 2715-2727.	0.7	11
159	Potent antitumor effects of intra-arterial injection of fibroblasts genetically engineered to express IL-12 in liver metastasis model of rat: No additional benefit of using retroviral producer cell. Cancer Gene Therapy, 2001, 8, 17-22.	2.2	9
160	Characteristics of Malignant Pleural Effusion Resident CD8+ T Cells from a Heterogeneous Collection of Tumors. International Journal of Molecular Sciences, 2020, 21, 6178.	1.8	9
161	A primer on cancer immunology and immunotherapy. Cancer Immunology, Immunotherapy, 2004, 53, 135-138.	2.0	8
162	The myeloid response to pancreatic carcinogenesis is regulated by the receptor for advanced glycation end-products. OncoImmunology, 2013, 2, e24184.	2.1	8

#	Article	IF	Citations
163	Serum IL27 in Relation to Risk of Hepatocellular Carcinoma in Two Nested Caseâ€“Control Studies. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 388-395.	1.1	8
164	Tumor Recognition by the Cellular Immune System: New Aspects of Tumor Immunology. International Reviews of Immunology, 1997, 14, 97-132.	1.5	7
165	Pancreatic Cancer Is Not Noble. Journal of Innate Immunity, 2012, 4, 4-5.	1.8	7
166	RAGE-specific single chain Fv for PET imaging of pancreatic cancer. PLoS ONE, 2018, 13, e0192821.	1.1	7
167	A peaceful death orchestrates immune balance in a chaotic environment. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22901-22903.	3.3	7
168	Ratcheting down the virulence of SARSâ€CoVâ€2 in the COVIDâ€19 pandemic. Journal of Medical Virology, 2020, 92, 2379-2380.	2.5	7
169	Gutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer. Journal of Immunotherapy, 2021, 44, 49-62.	1.2	7
170	Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes. European Journal of Immunology, 1996, 26, 2613-2623.	1.6	6
171	Cytolytic Assays. , 2005, , 343-349.		6
172	Autophagy inhibition is the next step in the treatment of glioblastoma patients following the Stupp era. Cancer Gene Therapy, 2020, 28, 971-983.	2.2	6
173	In Vivo Priming of Peritoneal Tumor-Reactive Lymphocytes With a Potent Oncolytic Virus for Adoptive Cell Therapy. Frontiers in Immunology, 2021, 12, 610042.	2.2	6
174	Sequestsome-1/p62-targeted small molecules for pancreatic cancer therapy. Drug Discovery Today, 2022, 27, 362-370.	3.2	6
175	Host immune response in renal cell cancer: Interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunology, Immunotherapy, 1995, 41, 111-121.	2.0	6
176	Introduction. Annals of the New York Academy of Sciences, 1996, 795, xiii-xix.	1.8	5
177	Inhibiting Autophagy in Renal Cell Cancer and the Associated Tumor Endothelium. Cancer Journal (Sudbury, Mass), 2019, 25, 165-177.	1.0	5
178	AllergoOncology: Danger signals in allergology and oncology: AÂEuropean Academy of Allergy and Clinical Immunology (EAACI) Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2594-2617.	2.7	5
179	HMGB1 Promotes Myeloid Egress and Limits Lymphatic Clearance of Malignant Pleural Effusions. Frontiers in Immunology, 2020, 11, 2027.	2.2	4
180	Dying dangerously: Necrotic cell death and chronic inflammation promote tumor growth. Discovery Medicine, 2004, 4, 448-56.	0.5	4

#	Article	IF	Citations
181	The Unknown Unknowns: Recovering Gamma-Delta T Cells for Control of Human Immunodeficiency Virus (HIV). Viruses, 2020, 12, 1455.	1.5	3
182	Intratumoral T cell clonality and survival in a randomized phase II study of preoperative autophagy inhibition in combination with gemcitabine and nab-paclitaxel treatment in patients with resectable pancreatic cancer.. Journal of Clinical Oncology, 2021, 39, e16001-e16001.	0.8	3
183	Experimental respiratory exposure to putative Gulf War toxins promotes persistent alveolar macrophage recruitment and pulmonary inflammation. Life Sciences, 2021, 282, 119839.	2.0	3
184	Distant skin and soft tissue metastases from sarcomas. Journal of Surgical Oncology, 1998, 69, 94-98.	0.8	3
185	Cancer as a chronic inflammatory disease: role of immunotherapy. , 2004, , 21-51.		3
186	Report on the ISBTC Mini-symposium on Biologic Effects of Targeted Therapeutics. Journal of Immunotherapy, 2007, 30, 577-590.	1.2	2
187	Parkinson Disease and Malignant Disease. JAMA Oncology, 2015, 1, 641.	3.4	2
188	In company. Nature, 1991, 353, 467-468.	13.7	1
189	A nexus of science and clinical immunology: The Federation of Clinical Immunology Societies and the FOCIS Centers of Excellence. Clinical Immunology, 2008, 127, 119-120.	1.4	1
190	Impact of G-CSF during neoadjuvant therapy on outcomes of operable pancreatic cancer.. Journal of Clinical Oncology, 2021, 39, 4126-4126.	0.8	1
191	High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. , 0, .		1
192	Outcomes and efficacy of neoadjuvant chemoradiation versus chemotherapy in localized pancreatic cancer.. Journal of Clinical Oncology, 2020, 38, 727-727.	0.8	1
193	The critical need for cancer biometrics: quantitative, reproducible measures of cancer to define response to therapy. Current Opinion in Investigational Drugs, 2003, 4, 649-51.	2.3	1
194	Gut microbiota composition and outcomes following neoadjuvant therapy in patients with localized pancreatic cancer: A prospective biomarker study.. Journal of Clinical Oncology, 2022, 40, 4143-4143.	0.8	1
195	Healing arts. Nature, 1990, 347, 587-588.	13.7	0
196	Interleukin-10 (IL-10). , 2007, , 165-179.		0
197	Tumor immunology and immunotherapy. , 2008, , 1181-1195.		0
198	Autophagy and the Tumor Microenvironment. , 2013, , 167-189.		0

#	Article	IF	Citations
199	IB-03 * IDH MUTANT GLIOMAS ARE RESISTANT TO NATURAL KILLER CELL-MEDIATED CYTOLYSIS. Neuro-Oncology, 2014, 16, v107-v107.	0.6	0
200	ASO Author Reflection: Viruses, the Lung, and Thoracic Neoplasms: Breaking Bad. Annals of Surgical Oncology, 2021, 28, 2728-2729.	0.7	0
201	Imaging Cytometry: High Content Screening for Large-Scale Cell Research. , 2005, , 660-665.		0
202	Activated Natural Killer Cells. , 2011, , 19-23.		0
203	Tumor immunotherapy. , 2013, , 935-945.		0
204	Activated Natural Killer Cells. , 2015, , 1-5.		0
205	Activated Natural Killer Cells. , 2015, , 26-30.		0
206	680â€…Isoforms of neuropilin-2 regulate distinct macrophage functions and are associated with unique tumor-associated macrophages in murine and human breast cancer. , 2021, 9, A708-A708.		0